Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026
Key Highlights
- ➤Palopegteriparatide data show normalized bone mass and microarchitecture over five years
- ➤Navepegritide improved growth and physical functioning in ApproaCH open-label extension
- ➤Navepegritide produced continued lower-extremity alignment improvements through Week 104
- ➤Phase 2 COACH reported 78-week results combining navepegritide with lonapegsomatropin
- ➤YUVIWEL European regulatory decision anticipated in fourth quarter of 2026
Expert Statements
Aimee Shu, Executive Vice President and Chief Medical Officer at Ascendis Pharma
“Our growing body of clinical trial data continues to illustrate the unique potential for our differentiated TransCon-based therapies to improve patient health and quality of life.”
Aimee Shu, Executive Vice President and Chief Medical Officer at Ascendis Pharma
“Compelling long-term data such as these help inform treatment paradigms focused on outcomes that matter most to patients, and we look forward to sharing additional results as our programs advance.”
COPENHAGEN, Denmark, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest advances in its hypoparathyroidism and achondroplasia programs will be showcased during ASBMR 2026, the annual meeting of American Society for Bone & Mineral Research being held in Boston from October 9-12, 2026. Updates include an oral presentation by Aliya Khan, M.D., of combined skeletal data from the Phase 2 PaTH Forward and Phase 3 PaTHway trials showing normalization of bone mass and microarchitecture in clinical trial patients treated with TransCon(®) PTH (palopegteriparatide) over a 5-year period.
“Our growing body of clinical trial data continues to illustrate the unique potential for our differentiated TransCon-based therapies to improve patient health and quality of life,” said Aimee Shu, M.D., Executive Vice President, Chief Medical Officer at Ascendis Pharma. “Compelling long-term data such as these help inform treatment paradigms focused on outcomes that matter most to patients, and we look forward to sharing additional results as our programs advance.”
Get started
Create a free account to read the full story.